| Cat.No. | Name | Information |
|---|---|---|
| M1861 | Silmitasertib (CX-4945) | CX-4945 (Silmitasertib) is a potent small molecule protein kinase inhibitor that selectively binds to and inhibits the enzyme casein kinase II (CK2). |
| M45305 | CK2-IN-9 | CK2-IN-9 is a potent selective inhibitor of CK2 kinase with an IC50 of 3 nM, and also reduces the reporter activity of Wnt with an IC50 of 75 nM. In addition, CK2-IN-9 is characterized by low exposure (AUC=0.36 μM/h) and high clearance (CL=65 mL/min/kg) in rats. |
| M45303 | CK2 inhibitor 3 | CK2 inhibitor 3 is a potent CK2 inhibitor with an IC50 of 280 nM that significantly affects tumor cell viability and exhibits significant selectivity for a panel of 320 kinases. |
| M45302 | CK2-IN-6 | CK2-IN-6 is a potent protein kinase CK2 inhibitor for use in studies related to cancer as well as other kinase-associated conditions, including inflammation, pain, and certain immune disorders. |
| M45301 | Casein Kinase II Substrate | Casein Kinase II Substrate is a casein kinase II (CK2) peptide substrate that is selectively phosphorylated by CK2. |
| M45300 | CK2/PIM1-IN-1 | CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1 with IC50 values of 3.787 μM and 4.327 μM for the effects of CK2 and PIM1, respectively.CAS 번호410483-84-5 |
| M45299 | c-Myc inhibitor 7 | c-Myc inhibitor 7 is a c-Myc inhibitor and multi-targeted protein degrader. c-Myc inhibitor 7 effectively degrades c-Myc, CK1α, GSPT1 and IKZF1/2/3 proteins in a variety of tumor cells. It can also be used in the study of diseases with high c-Myc expression. |
| M45298 | Umbralisib tosylate | Umbralisib tosylate is an orally potent, selective dual inhibitor of PI3Kδ and casein kinase-1-ε (CK1ε) with EC50s of 22.2 nM and 6.0 μM, respectively.Additionally, Umbralisib tosylate has demonstrated unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib tosylate Umbralisib tosylate can be used in the study of hematologic malignancies. |
| M45297 | CK2-IN-3 | CK2-IN-3 is a selective and potent CK2 inhibitor (Kd: 12 nM) with IC50 values of 1.51 μM (CK2α), 7.64 μM (CK2α') and can be used in cancer-related studies. |
| M45296 | Umbralisib sulfate | Umbralisib sulfate is an orally potent, selective dual inhibitor of PI3Kδ and casein kinase-1-ε (CK1ε) with EC50s of 22.2 nM and 6.0 μM, respectively.Additionally, Umbralisib sulfate has demonstrated unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used in the study of hematologic malignancies. |
| M45295 | Casein Kinase II Inhibitor IV hydrochloride | Casein Kinase II Inhibitor IV hydrochloride is a potent ATP-competitive casein kinase II inhibitor with an IC50 of 9 nM. In addition, Casein Kinase II Inhibitor IV is a human keratinocyte (NHEK) differentiation inducer. In addition, Casein Kinase II Inhibitor IV is a human keratinocyte (NHEK) differentiation inducer. |
| M45294 | Casein Kinase 2 Substrate Peptide | Casein Kinase 2 Substrate Peptide is a common CK2 substrate peptide that is C-terminally bound to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). It can be used for the determination of protein kinase CK2 activity. |
| M45293 | BRD4/CK2-IN-1 | BRD4/CK2-IN-1 is a potent, orally active dual-targeted inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2) with IC50 values of 180 nM and 230 nM, respectively.BRD4/CK2-IN-1 exhibits potent anticancer activity without significant toxicity and induces apoptosis and autophagy-related cell death in triple-negative breast cancer (TNBC). autophagy-related cell death in triple negative breast cancer (TNBC). |
| M45292 | TBCA | TBCA is a highly selective inhibitor of casein kinase II CK2 with an IC50 of 110 nM and a Ki of 77 nM.In addition, TBCA exhibits selectivity for CK1, DYRK1A and 27 other kinases. |
| M45291 | MU1742 | MU1742 is a probe that can be used to detect CK1δ and CK1ε kinases. |
| M45290 | TMX-4113 | TMX-4113 is a phosphodiesterase 6D (PDE6D) and casein kinase 1alpha (CK1alpha) degrader for cancer-related studies. |
| M45288 | Casein Kinase inhibitor A86 | Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor that also inhibits CDK7 (TFIIH) and CDK9 (P-TEFb). In addition, Casein Kinase inhibitor A86 induces apoptosis in leukemia cells and may be used in leukemia-related studies. |
| M45287 | CK2/ERK8-IN-1 | CK2/ERK8-IN-1 is a dual inhibitor of casein kinase 2 (CK2) (Ki 0.25 µM) and ERK8 (MAPK15, ERK7), both with IC50s of 0.50 µM. In addition, CK2/ERK8-IN-1 binds to PIM1, HIPK2, and DYRK1A with Ki values of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. 15.25 µM and 11.9 µM, respectively, and also has pro-apoptotic activity. |
| M45286 | MRT00033659 | MRT00033659 is a pyrazolopyridine analog that induces p53 pathway activation. It is also a potent broad-spectrum kinase inhibitor that inhibits CK1 (for CK1δ: IC50=0.9 µM) and CHK1 (IC50=0.23 µM). |
| M45283 | BTX161 | BTX161 is a Thalidomide analog and potent CKIα degrader.BTX161 mediates the degradation of CKIα better than Lenalidomide and activates the DNA damage response (DDR) and p53 while stabilizing the p53 antagonist MDM2 in human AML cells. |
| M45282 | CKI-7 free base | CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. In addition, CKI-7 free base selectively inhibits Cdc7 kinase, SGK, S6K1 and MSK1. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
